A phase Ib study of the combination of the aurora kinase inhibitor alisertib (MLN8237) and bortezomib in relapsed multiple myeloma

Allison Rosenthal, Shaji Kumar, Craig Hofmeister, Jacob Laubach, Ravi Vij, Amylou Dueck, Katherine Gano, A. Keith Stewart

Research output: Contribution to journalLetter

14 Scopus citations
Original languageEnglish
Pages (from-to)323-325
Number of pages3
JournalBritish Journal of Haematology
Issue number2
StatePublished - Jul 1 2016


  • Alisertib
  • Aurora kinase
  • Bortezomib
  • Multiple myeloma
  • Relapse

Cite this